Home » Digital adherence technologies in tuberculosis

Digital adherence technologies in tuberculosis

Gaye Hafez1 and Job F M van Boven2

 
Affiliations 
  • 1Department of Pharmacology, Faculty of Pharmacy,
    Altinbas University, Istanbul 34140, Türkiye
  • 2Department of Clinical Pharmacy and Pharmacology, Medication Adherence Expertise
    Center of the Northern Netherlands, University
    Medical Center Groningen, University of Groningen,
    Groningen, Netherlands

With great interest, we read the cluster-randomised superiority trial by Xiaoqiu Liu and colleagues, published in The Lancet Global Health . The authors should be applauded for providing this large and important study investigating the use of digital adherence technology to support tuberculosis treatment. However, although adherence rates were slightly improved in the intervention group, no effect on the primary composite outcome of death, loss to follow-up or stopping treatment, treatment failure, switch to multidrug-resistant tuberculosis treatment, or tuberculosis recurrence by 18 months from treatment start was shown. [….]

Hafez G, van Boven JFM. Digital adherence technologies in tuberculosis. Lancet Glob Health. 2023 Sep;11(9):e1341-e1342. doi: 10.1016/S2214-109X(23)00308-X. PMID: 37591581.

 

https://www.thelancet.com/action/showPdf?pii=S2214-109X%2823%2900308-X